Nuvation Bio (NUVB) Long-Term Deferred Tax (2020 - 2025)
Nuvation Bio (NUVB) posted quarterly Long-Term Deferred Tax of $245.0 million for Q4 2025, up 127.46% year-over-year from $107.7 million in Q4 2024, and up 127.46% quarter-over-quarter from $107.7 million in Q4 2024.
Nuvation Bio (NUVB) Long-Term Deferred Tax (2020 - 2025) Analysis & Trends
Nuvation Bio (NUVB) has reported Long-Term Deferred Tax for 3 consecutive years, with $245.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 127.46% year-over-year to $245.0 million; the TTM figure through Dec 2025 stood at $245.0 million (up 127.46% YoY), while the FY2025 annual figure was $245.0 million, up 127.46% from the prior year.
- Long-Term Deferred Tax improved to $245.0 million in Q4 2025 per NUVB's latest filing, from $107.7 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $245.0 million in Q4 2025 and bottomed at $107.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 244.97 Mn |
| Dec 31, 2024 | 107.70 Mn |
| Sep 30, 2020 | 154,000.00 |
| Jun 30, 2020 | 167,736.00 |